EU/3/01/021:

imatinib mesilate

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2011 at the end of the period of market exclusivity.

On 14 February 2001, orphan designation (EU/3/01/021) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for imatinib mesilate for the treatment of chronic myeloid leukaemia.

Imatinib mesilate for treatment of chronic myeloid leukaemia has been authorised in the EU as Glivec since 7 November 2001.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
imatinib mesilate
Medicine name
Glivec
Intented use
Treatment of chronic myeloid leukaemia
Date of designation
15/02/2001
Orphan designation status
Expired
EU designation number
EU/3/01/021

Sponsor's contact details

Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom
Tel. +41 61 324 11 11 (Switzerland)
E-mail: orphan.enquiries@novartis.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating